Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets

Report Code: BIO071B

Publish Date: Oct 2012

Publisher: BCC Publishing

Category: Cell Biology

Customize This Report

Single User License: $2500

Member Price: FREE

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global aptamer market was valued at $40 million in 2011 and should reach nearly $99 million in 2012. Total market value is expected to reach nearly $3.7 billion in 2017 with a five-year compound annual growth rate (CAGR) of 106.3%.

Report Includes

  • An overview of the specific applications for nucleic acid aptamers for therapeutic and diagnostic purposes, with a focus on applications judged to be commercially viable rather than enabling of basic research
  • Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
  • Identification of emerging technology growth opportunities in aptamer use as adjuvants for siRNA delivery, vaccines, and antisense technologies
  • Examination of high growth and market potential segments of the industry, and new and established companies in the arena
  • Comprehensive company profiles of major players in the industry.

Report Scope

The scope of this report covers all major known applications of aptamers in the biotechnology arena.  Nevertheless, the study focuses on applications judged to be commercially viable rather than enabling of basic research.

Analyst Credentials

Dr. George William (“Bill”) Jackson, Ph.D., serves as a Senior Scientist at BioTex, Inc. in Houston, Texas.  Additionally, Dr. Jackson is founder and chief scientist of Base Pair Biotechnologies, Inc., a company specializing in aptamer discovery services.  He is an active researcher in the molecular biology and diagnostics field with numerous federal grants in the area.  Particularly, he has served as principal investigator (PI) on several projects utilizing aptamers for both sensing and bioremediation.  Most recently, he serves as PI on a research grant from the National Institutes of Health to select “an aptamer to everything,” which was formally titled, “Platform for Massively Parallel Selection of Aptamer Ligands.” He has served on peer review panels at the National Institutes of Health and the Environmental Protection Agency on topics ranging from biodefense and medical diagnostics to water quality.  Dr. Jackson has authored more than 30 peer-reviewed publications or conference proceedings and is the inventor on four issued and 13 pending patents.

Co-author, Dr. Ulrich Strych, Ph.D., is a Research Assistant Professor at the University of Houston.  Dr. Strych is an experienced molecular biologist who has collaborated with Dr. Jackson for more than five years on various aptamer-related research projects.  Dr. Strych has extensive modern molecular biology experience, methods development know-how in surface plasmon resonance (SPR) and other bioanalytical approaches, and hands-on experience with other methods of high-throughput combinatorial screening, such as phage display.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW
Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets137Free
Chapter- 1: INTRODUCTION3Free
Chapter- 2: SUMMARY4Free
Chapter- 3: OVERVIEW5Free
Chapter- 4: MARKETS BY TECHNOLOGY TYPE43Free
Chapter- 5: MARKETS BY APPLICATIONS20Free
Chapter- 6: INTELLECTUAL PROPERTY ANALYSIS16Free
Chapter- 7: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS9Free
Chapter- 8: C. CRAMER & CO. GMBH15Free
Published - Mar-2010| Analyst - George W. Jackson| Code - BIO071A

Report Highlights

  • The global market for aptamers is poised for significant new market entrants in the near future. In 2009 this market was valued at $10 million. By 2014, this market is estimated to be worth $1.9 billion, a compound annual growth rate (CAGR) of nearly 68%.
  • Aptamer therapeutic markets were valued at $10 million in 2009 and should increase at a 55% compound annual growth rate (CAGR) to $1.2 billion in 2014.
  • Aptamer diagnostic markets were worth $26 million in 2010 and are expected to increase in value to $659 million in 2014, a compound annual growth rate (CAGR) of 124%.

Related Reports

Global Biochip Markets: Microarrays and Lab-on-a-Chip

Published - Aug 2011 | Publisher - John Bergin | Code - BIO049D

The global value of the overall biochips market, by end use was $3.5 billion in the year 2010. The size of the biochips market will increase from $3.9 billion in 2011 to nearly $9.6 billion by 2016, a compound annual growth rate (CAGR) of 19.5%.

Recent Reports

Artificial Intelligence (AI) in Cancer

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO196B

The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Induced Pluripotent Stem Cells: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO135F

The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.

Commercial Amino Acids

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO007N

The global market for commercial amino acids was valued at $30.1 billion in 2023. It is expected to grow from $31.8 billion in 2024 to $42.8 billion by 2029, at a compound annual growth rate (CAGR) of 6.1% from 2024 through 2029.

Top Trending Reports

AI in Clinical and Molecular Diagnostics Market

Published - Oct 2024 | Publisher - BCC Publishing | Code - BIO261A

The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.

Point-of-Care Diagnostics: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC043H

The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.

Medical Devices: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC170F

The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

Global Artificial Intelligence (AI) Market: Investments vs Potential

Published - Aug 2024 | Publisher - BCC Publishing | Code - IFT189C

The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.

CRISPR Technology: Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC258C

The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
Customize Report